VyvanseTreatment for Attention Deficit Disorder
Update: Vyvanse Now FDA Approved - February 23, 2007
New River Pharmaceuticals Announces NRP104 NDA Accepted for Review
RADFORD, Va., January 27, 2006 -- New River Pharmaceuticals Inc. announced that on January 26, the U.S. Food and Drug Administration accepted for review the Company's new drug application (NDA) for NRP104. New River submitted the NDA on December 6, 2005, seeking approval to manufacture and market the investigational compound for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric populations (ages 6-12). NRP104 is the subject of a collaborative development and commercialization agreement between New River and Shire plc .
"We are pleased that this NDA has been accepted for review," commented Suma Krishnan, New River's Vice President, Product Development. "This represents a key milestone in NRP104's regulatory development. We remain hopeful that this promising drug candidate will be approved and launched by the end of 2006."
The acceptance for review of the NDA represents the FDA's determination that the application is sufficiently complete to permit a substantive review. It does not represent any opinion regarding the safety, efficacy or approvability of NRP104.
Posted: January 2006
- FDA Expands Uses of Vyvanse to Treat Binge-Eating Disorder - January 30, 2015
- Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) Now Approved in the US for Maintenance Treatment in Adults with ADHD - February 7, 2012
- FDA Approves Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents - November 15, 2010
- FDA Approves Labeling Change for Vyvanse (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD - June 1, 2009
- FDA Approves Vyvanse (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults - April 23, 2008
- FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment Vyvanse (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients - January 3, 2008
- Shire Receives FDA Approval of Vyvanse for ADHD - February 26, 2007
- New River Pharmaceuticals and Shire Receive Approvable Letter for Vyvanse - December 21, 2006
- FDA Issues Approvable Letter for NRP104 (lisdexamfetamine dimesylate) for the Treatment of ADHD - October 6, 2006
- Shire Announces New River Pharmaceuticals Filing of NRP104 - December 7, 2005
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.